CopyPastehas never been so tasty!

The Pharmaceutical Market : Germany

by anonymous

  • 0
  • 0
  • 0
55 views

Germany has one of the most advanced economies in the world. It is the fourth largest, behind the USA, China and Japan. According to the Economist Intelligence Unit (EIU), Germany’s toughest challenge and largest risk to stability in the 2012-2017 period will be the euro area debt crisis. Germany spends more on health than any other European country, but expenditure is not projected to grow rapidly over the next five years. The percentage of GDP spent on health is expected to remain around the same over the forecast period. http://www.bharatbook.com/market-research-reports/healthcare-market-research-report/the-pharmaceutical-market-germany.html

The German pharmaceutical market is twice the size of Italy; in per capita terms, it is similar to France. OTCs represent around 12% of the market and generics account for over a third. The market is predicted to increase at a low CAGR between 2012 and 2017. Growth in recent years has tended to be uneven, as government reforms take effect on pricing and/or reimbursement. A new law passed in November 2010 designed to bring down the average price of drugs is expected to dampen growth slightly over the next few years. The law reduces the power that pharmaceutical companies have in deciding what to charge for new prescription drugs. New, innovative drugs have been targeted as they were entirely responsible for the increase in drug spending in 2009. The German biologic market is expanding; biopharmaceuticals are expected to represent a fifth of the overall pharmaceutical market by 2020, according to Sandoz.

Reimbursement changes and greater use of substitution have placed a lot of pressure on older branded drugs, and prescribers and patients have been given financial incentives to switch to generics. However, reforms have not been especially ‘pro-generic’, so whilst generics will continue to be increasingly widely prescribed, their value share of the overall market will alter less rapidly. Generic drugs in Germany account for over a third of the prescription market by value. In volume terms, the generic market has continued to grow each year. In November 2011, Stada Arzneimittel signed a deal to acquire Spirig Pharma’s generic business.

PROVIDING STRATEGIC MARKET ANALYSIS EVERY MONTH
Espicom's highly-regarded world pharmaceutical market research reports provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:


Market size and trends impacting the development of the market.
Five-year projections for market indicators such as health spending.
Regulations on drug applications & approvals, pricing & reimbursement as well as wholesaling and retail.
Specialised intelligence on generics and biological medicines.
Foreign and local company profiles

EXECUTIVE SUMMARY...... 1
Snapshot: Strategic Espicom Analysis.....2
Snapshot: Key Data Projections.3
MACROENVIRONMENT..... 4
POLITICAL....4
ECONOMIC ..5
Projections ....5
LEGAL....6
EU Patent Protection & Intellectual Property Rights......6
Proposal for Unitary Patent..... 6
EU Supplementary Protection Certificates.6
EU Data Exclusivity.....6
DEMOGRAPHIC .7
Projections ....7
Demographic Indicators...8
Births.. 8
Deaths...... 8
Infant Deaths.. 8
Life Expectancy at Birth.... 8
EPIDEMIOLOGY... 9
DISEASE BURDEN.....9
Leading Causes of Mortality....9
DISEASE PREVALENCE..10
Communicable Diseases.10
HIV/AIDS. 10
Non-Communicable Diseases ......11
Cancer..... 11
HEALTHCARE - ACCOMPANYING HEALTH STATISTICS . 12
EU DIRECTIVE...12
Cross-Border Healthcare Directive .....12
ORGANISATION......12
Federal Ministries.....12
Länder Institutions...13
Healthcare System Reform....14
Health Insurance for All ..14
Improvement of Medical Care......14
Outpatient Care.. 14
Claim to Vaccination and Spa Treatments...... 14
Claim to Home Nursing... 14
Claim to Reasonable Rehabilitative Services. 14
Medicines...... 14
Modernisation of the Statutory and Private Health Funds.15
Bespoke Services – Two Examples of New Tariffs 15
Basic Tariff for Private Health Insurance .. 15
Reforming the Financing Base: The Health Fund...16
EXPENDITURE..17
Projections ..17
Latest Figures.....18
Social Security....18
Health Insurance Reform Approved by Government. 19
INFRASTRUCTURE. 20
Hospital Infrastructure ...20
Ambulatory Infrastructure....21
Care Services22
SERVICES... 23
Hospital Inpatient Services ...23
WORKFORCE... 25
Projections ..25
REGULATORY AFFAIRS ... 28
EU REGULATORY AUTHORITY.. 28
NATIONAL AUTHORITY...... 28
MARKETING REGISTRATION..... 28
EU Marketing Registration....28
Centralised Procedure.....28
National Regulation.29
PRICING & REIMBURSEMENT 30
EU NETWORKING MEETING...... 30
NM CAPR......30
PRICING .... 30
New Law Regarding Prescription Drug Prices......30
Pharmaceutical Discount Contracts.. 31
Generic Substitution Policies 31
Compulsory Manufacturer Rebates... 31
AVWG...... 31
REIMBURSEMENT ..31
DISTRIBUTION CHANNELS.... 32
EU DIRECTIVE...32
Falsified Medicines Directive.32
DRUG WHOLESALING...32
Association of Wholesalers....32
PHAGRO .32
Leading Wholesalers33
Anzag......33
Celesio ....33
Noweda eG...33
Phoenix AG...33
Sanacorp Pharmahandel AG.33
DRUG RETAILING... 34
MARKET ANALYSIS... 35
SIZE......35
Projections ..35
Historical Figures......37
Current Structure......38
Retail Pharmaceutical Expenditure...38
GKV Drug Expenditure....40
Hospital-only Drugs Expenditure ...... 41
PRODUCT DEVELOPMENT..42
EU Programmes.42
Horizon 202042
IMI.....42
National Product Development...42
MANUFACTURING..43
TRADE 44

For more information kindly visit :
The Pharmaceutical Market : Germany

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: https://twitter.com/BharatBook
Our Blogs: http://in.linkedin.com/pub/bharat-book/3a/98/512
http://financemarketreports.blogspot.com/

Add A Comment: